Literature DB >> 26880022

Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson's disease.

Thomas Müller1,2, Isabel Trommer3, Siegfried Muhlack4, Bernhard K Mueller3.   

Abstract

Exposure to free radicals influences synthesis, degradation and function of proteins, such as repulsive guidance molecule A. Decay of this protein is essential for neuronal maintenance and recovery. Levodopa elevates oxidative stress. Therefore levodopa may impact repulsive guidance molecule A metabolism. Objectives were to investigate plasma concentrations of repulsive guidance molecule A, levodopa, cysteine and cysteinyl-glycine before and 1 h after levodopa application in patients with Parkinson's disease. Cysteine and cysteinyl-glycine as biomarkers for oxidative stress exposure decreased, repulsive guidance molecule A and levodopa rose. Repulsive guidance molecule A remained unchanged in levodopa naïve patients, but particularly went up in patients on a prior chronic levodopa regimen. Decay of cysteine specifically cysteinyl-glycine results from an elevated glutathione generation with rising cysteine consumption respectively from the alternative glutathione transformation to its oxidized form glutathione disulfide after free radical scavenging. Repulsive guidance molecule A rise may inhibit physiologic mechanisms for neuronal survival.

Entities:  

Keywords:  Cysteine; Cysteinyl-glycine; Levodopa; Oxidative stress; Parkinson’s disease; Repulsive guidance molecule A

Mesh:

Substances:

Year:  2016        PMID: 26880022     DOI: 10.1007/s00702-016-1519-4

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  26 in total

1.  Levodopa deactivates enzymes that regulate thiol-disulfide homeostasis and promotes neuronal cell death: implications for therapy of Parkinson's disease.

Authors:  Elizabeth A Sabens; Anne M Distler; John J Mieyal
Journal:  Biochemistry       Date:  2010-03-30       Impact factor: 3.162

2.  Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients.

Authors:  Thomas Müller; Siegfried Muhlack
Journal:  J Neural Transm (Vienna)       Date:  2014-01-05       Impact factor: 3.575

3.  Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients.

Authors:  Thomas Müller; Siegfried Muhlack
Journal:  Mov Disord       Date:  2011-02-15       Impact factor: 10.338

4.  Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.

Authors: 
Journal:  JAMA       Date:  2002-04-03       Impact factor: 56.272

5.  Induction of repulsive guidance molecule in neurons following sciatic nerve injury.

Authors:  Hideo Doya; Toshinori Ito; Katsuhiko Hata; Masashi Fujitani; Seiji Ohtori; Tomoko Saito-Watanabe; Hideshige Moriya; Kazuhisa Takahashi; Takekazu Kubo; Toshihide Yamashita
Journal:  J Chem Neuroanat       Date:  2006-07-24       Impact factor: 3.052

6.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.

Authors:  Alan L Whone; Ray L Watts; A Jon Stoessl; Margaret Davis; Sven Reske; Claude Nahmias; Anthony E Lang; Olivier Rascol; Maria J Ribeiro; Philippe Remy; Werner H Poewe; Robert A Hauser; David J Brooks
Journal:  Ann Neurol       Date:  2003-07       Impact factor: 10.422

7.  Methyl group-donating vitamins elevate 3-O-methyldopa in patients with Parkinson disease.

Authors:  Thomas Müller; Constanze Jugel; Siegfried Muhlack; Fabian Klostermann
Journal:  Clin Neuropharmacol       Date:  2013 Mar-Apr       Impact factor: 1.592

8.  Decreased levels of repulsive guidance molecule A in association with beneficial effects of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients.

Authors:  Thomas Müller; Stefan Barghorn; Sven Lütge; Thomas Haas; Reinhold Mueller; Bjoern Gerlach; Gabi Öhm; Katrin Eilert; Isabel Trommer; Bernhard K Mueller
Journal:  J Neural Transm (Vienna)       Date:  2014-09-11       Impact factor: 3.575

9.  Neuropathy in Parkinson's disease patients with intestinal levodopa infusion versus oral drugs.

Authors:  Constanze Jugel; Felicitas Ehlen; Birol Taskin; Frank Marzinzik; Thomas Müller; Fabian Klostermann
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

10.  RGMa inhibition promotes axonal growth and recovery after spinal cord injury.

Authors:  Katsuhiko Hata; Masashi Fujitani; Yuichi Yasuda; Hideo Doya; Tomoko Saito; Satoru Yamagishi; Bernhard K Mueller; Toshihide Yamashita
Journal:  J Cell Biol       Date:  2006-04-03       Impact factor: 10.539

View more
  11 in total

1.  Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.

Authors:  Joanna A Korecka; Elizabeth B Moloney; Ruben Eggers; Barbara Hobo; Sanny Scheffer; Nienke Ras-Verloop; R Jeroen Pasterkamp; Dick F Swaab; August B Smit; Ronald E van Kesteren; Koen Bossers; Joost Verhaagen
Journal:  J Neurosci       Date:  2017-08-21       Impact factor: 6.167

2.  Vitamin D rise enhances blood perfusion in patients with multiple sclerosis.

Authors:  Thomas Müller; Lutz Lohse; Andreas Blodau; Katja Frommholz
Journal:  J Neural Transm (Vienna)       Date:  2019-10-16       Impact factor: 3.575

Review 3.  Perspective: Treatment for Disease Modification in Chronic Neurodegeneration.

Authors:  Thomas Müller; Bernhard Klaus Mueller; Peter Riederer
Journal:  Cells       Date:  2021-04-12       Impact factor: 6.600

4.  Variation in the repulsive guidance molecule family in human populations.

Authors:  Peter Rotwein
Journal:  Physiol Rep       Date:  2019-02

5.  Embelin and levodopa combination therapy for improved Parkinson's disease treatment.

Authors:  Vagdevi Hangarakatte Ramachandra; Senthilkumar Sivanesan; Anand Koppal; Shanmugam Anandakumar; Matthew D Howell; Ethirajan Sukumar; Rajagopalan Vijayaraghavan
Journal:  Transl Neurosci       Date:  2022-06-29       Impact factor: 1.264

Review 6.  View Point: Disease Modification and Cell Secretome Based Approaches in Parkinson's Disease: Are We on the Right Track?

Authors:  Thomas Müller
Journal:  Biologics       Date:  2021-07-29

7.  Do we need a new levodopa?

Authors:  Thomas Müller
Journal:  Neural Regen Res       Date:  2016-05       Impact factor: 5.135

8.  Serum amino acid profile in patients with Parkinson's disease.

Authors:  Monika Figura; Katarzyna Kuśmierska; Ewelina Bucior; Stanisław Szlufik; Dariusz Koziorowski; Zygmunt Jamrozik; Piotr Janik
Journal:  PLoS One       Date:  2018-01-29       Impact factor: 3.240

9.  Repulsive Guidance Molecule a Inhibits Angiogenesis by Downregulating VEGF and Phosphorylated Focal Adhesion Kinase In Vitro.

Authors:  Gang Zhang; Rong Wang; Ke Cheng; Qi Li; Yu Wang; Rongrong Zhang; Xinyue Qin
Journal:  Front Neurol       Date:  2017-09-26       Impact factor: 4.003

10.  Dietary Approaches to Improve Efficacy and Control Side Effects of Levodopa Therapy in Parkinson's Disease: A Systematic Review.

Authors:  Jikke T Boelens Keun; Ilse Ac Arnoldussen; Chris Vriend; Ondine van de Rest
Journal:  Adv Nutr       Date:  2021-12-01       Impact factor: 8.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.